Biohaven Pharmaceuticals Holdings

  • TickerBHVN
  • ISINVGG111961055
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Kenneth Shields ...
  • Laura Chico

Weekly Neurology Prescription Sales Tracker -- Week Ending 6/4/21

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...

Biohaven Pharmaceutical Holding Co Ltd: 1 director bought

A director at Biohaven Pharmaceutical Holding Co Ltd bought 25,000 shares at 61.539USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing r...

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Kenneth Shields ...
  • Laura Chico

Weekly Neurology Prescription Sales Tracker -- Week Ending 6/4/21

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Thanks to a better fundamental star rating, BIOHAVEN PHARMA sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to BIOHAVEN PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 5, 2021, the closing price was USD 84.03 and its expected value was estimated at USD 84.67.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch